DYN logo

DYN
Dyne Therapeutics Inc

2,691
Mkt Cap
$3.2B
Volume
1.5M
52W High
$25.00
52W Low
$8.06
PE Ratio
-5.99
DYN Fundamentals
Price
$19.33
Prev Close
$18.56
Open
$18.65
50D MA
$18.27
Beta
1.92
Avg. Volume
1.75M
EPS (Annual)
-$3.47
P/B
3.69
Rev/Employee
$0.00
$1,570.98
Loading...
Loading...
News
all
press releases
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Key PointsFCPM III sold 818,460 shares of Dyne Therapeutics last quarter; the estimated transaction value was $14.11 million based on average prices...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dystrophy.
Zacks
News Placeholder
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.
Zacks
News Placeholder
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside
Dyne said it plans to submit an application seeking accelerated approval of z-rostudirsen to the U.S. Food and Drug Administration later this quarter.
Stocktwits
News Placeholder
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
Key PointsSaturn V sold 822,007 shares of Dyne Therapeutics in the first quarter; the estimated transaction value was $14.17 million based on quarterly average prices...
Nasdaq News: Markets
News Placeholder
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
Dyne Therapeutics Q1 Net Loss Widens
(RTTNews) - Dyne Therapeutics, Inc. (DYN) reported Monday that net loss for the first quarter was $120.85 million or $0.73 per share, compared to net loss of $115.36 million or $1.05 per share in the prior-year quarter...
Nasdaq News: Markets
News Placeholder
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,600 Shares
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,600 shares of the business's stock in a transaction on Tuesday, May 5th. The shares were sold at an average price...
MarketBeat
News Placeholder
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,904 Shares
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,904 shares of the company's stock in a transaction on Monday, May 4th. The stock was sold at an average price of...
MarketBeat
News Placeholder
Wall Street Zen Downgrades Dyne Therapeutics (NASDAQ:DYN) to Strong Sell
Wall Street Zen lowered shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available